Document Detail


Comparison of the effects of quinapril and irbesartan on P-wave dispersion in hypertensive patients.
MedLine Citation:
PMID:  18670740     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
INTRODUCTION: P-wave dispersion (PWD) has been shown to be a non-invasive electrocardiographic predictor for development of atrial fibrillation (AF). Thus, it may be possible to attenuate AF risk through improvement of PWD. In this study, we compared the effects of an angiotensin-converting enzyme (ACE) inhibitor, quinapril, and an angiotensin receptor blocker (ARB), irbesartan, on PWD. METHODS: A total of 38 newly diagnosed hypertensive patients were enrolled in the study. The patients were randomly assigned to receive treatment with either irbesartan (150-300 mg) or quinapril (20-40 mg). P-wave durations and PWD were measured at baseline and after 6 and 12 months of treatment. Echocardiographic examinations were performed at baseline and after 12 months of treatment. RESULTS: Both drugs significantly reduced blood pressure to a similar degree (P<0.001). Deceleration time (both P<0.001) and isovolumetric relaxation time (both P=0.007) were also significantly reduced, whereas there was no significant change in the early diastolic flow/atrial contraction signal ratio. Both irbesartan and quinapril significantly decreased maximum P-wave duration (Pmax) (P<0.001 and P=0.002, respectively) and PWD (from 68.0+/-22.1 to 41.0+/-25.1 msec for irbesartan, and from 70.5+/-20.4 to 46.6+/-13.3 msec for quinapril; both P<0.001). Baseline and follow-up blood pressure, heart rate, echocardiographic findings, and P-wave values were not significantly different between the irbesartan and quinapril groups. No patient developed AF during follow-up. There was no significant correlation between PWD and blood pressure or diastolic function parameters. CONCLUSION: Antihypertensive treatment with either irbesartan or quinapril is associated with significant reductions in Pmax and PWD.
Authors:
Unal Guntekin; Yilmaz Gunes; Mustafa Tuncer; Hakki Simsek; Ahmet Gunes
Publication Detail:
Type:  Comparative Study; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Advances in therapy     Volume:  25     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:  2008 Aug 
Date Detail:
Created Date:  2008-08-21     Completed Date:  2009-01-22     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  775-86     Citation Subset:  T    
Affiliation:
Yuzunci Yil University, Faculty of Medicine, Cardiology Department, Van, Turkey. guntekinunal@hotmail.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Angiotensin II Type 1 Receptor Blockers / therapeutic use*
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Antihypertensive Agents / therapeutic use*
Atrial Fibrillation / etiology,  prevention & control
Biphenyl Compounds / therapeutic use*
Blood Pressure / drug effects
Electrocardiography / drug effects*
Female
Humans
Hypertension / complications,  drug therapy,  physiopathology*
Male
Middle Aged
Tetrahydroisoquinolines / therapeutic use*
Tetrazoles / therapeutic use*
Chemical
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents; 0/Biphenyl Compounds; 0/Tetrahydroisoquinolines; 0/Tetrazoles; 138402-11-6/irbesartan; 82586-55-8/quinapril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Optimization of enzymatic clarification of sapodilla juice: a statistical perspective.
Next Document:  Serum YKL-40 levels as a prognostic factor in patients with locally advanced breast cancer.